For clinical therapy, TRAIL and the death receptor agonistic antibodies are under phase II clinical trials in colorectal cancer treatment due to TRAIL’s harmfulness to cancer cells compared with healthy cells [28,30]. The gene discussed is TNFSF10; the disease is cancer.